Using Re-Aim To Identify Implementation Determinants Of Cardiovascular Risk Stratification Score For Patients With Prostate Cancer

BackgroundCardiovascular disease (CVD) remains the leading cause of death among patients with prostate cancer. While the American Heart Associations PREVENT Score offers a comprehensive lab-based CVD risk prediction model, its integration into oncology workflows is hindered by logistical barriers. To address this gap, the GUHA-STABELLINI Score was developed as a simplified, lab-independent tool tailored for use in specialty care settings. ObjectiveTo evaluate physician preferences, implementation feasibility, and contextual fit of the GUHA-STABELLINI versus PREVENT Score using the RE-AIM (i.e., Reach, Effectiveness, Adoption, Implementation, and Maintenance) model. MethodsA cross-sectional survey was administered to 45 oncology-specialized physicians across academic and community settings. The survey, structured around RE-AIM domains, assessed preferences, implementation perceptions, and perceived effectiveness of each tool. Quantitative responses were analyzed descriptively, and qualitative comments were thematically coded. ResultsA significant majority (93%) of respondents preferred the GUHA-STABELLINI Score over PREVENT, citing its ease of use and alignment with clinical workflows. Across RE-AIM domains, GUHA-STABELLINI scored highly in adaptability (71%), cost/resource feasibility (65%), perceived effectiveness (87%), and equity of reach and outcomes (75% and 73%, respectively). Respondents emphasized the tools real-time usability, low resource dependency, and ability to facilitate shared decision-making without laboratory input. ConclusionsDespite marginally lower predictive precision, the GUHA-STABELLINI Score demonstrates superior feasibility, reach, and clinical utility within oncology clinics. Findings highlight the importance of implementation-informed design in developing decision support tools. Future research should focus on validating clinical outcomes and expanding use across specialties. The GUHA-STABELLINI Score serves as a model for pragmatic, specialty-integrated preventive care solutions in resource-constrained environments. QuestionAmong oncology-specialized physicians, does the simplified and laboratory-independent GUHA-STABELLINI cardiovascular risk score offer superior perceived implementability and clinical utility compared with the AHA PREVENT Score for prostate cancer patients on androgen deprivation therapy? FindingsIn this cross-sectional survey of 45 physicians, 93% preferred the GUHA-STABELLINI Score over the AHA PREVENT Score. Respondents rated GUHA-STABELLINI as highly adaptable to workflow (71%), cost- and resource-feasible (65%), and likely to be effective (87%) and equitable in reach (75%), despite its slightly lower predictive precision. MeaningA context-aligned, low-burden cardiovascular risk tool such as GUHA-STABELLINI may achieve greater clinical uptake in oncology settings than more complex laboratory-dependent models, highlighting the central role of implementation-informed design in successful adoption.